ROCKVILLE, Maryland, July 4, 2026
Immunomic Therapeutics Inc. (ITI), a clinical-stage biotechnology company and subsidiary of HLB, has announced the first patient dosing in its Phase 1 clinical trial of ITI-9001, an investigational next-generation allergy vaccine designed to treat Japanese cedar pollen allergy. The milestone was achieved less than one month after the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan cleared the clinical trial application, highlighting the company’s ability to rapidly advance innovative immunotherapy programs into human studies. ITI-9001 combines Immunomic Therapeutics’ proprietary UNITE® platform with self-amplifying RNA (saRNA) technology, aiming to provide a disease-modifying treatment that addresses the underlying immune mechanisms responsible for allergic disease rather than offering temporary symptom relief. The first participant successfully completed the initial post-dose safety monitoring visit, and the company reported no significant adverse events or safety concerns, marking a positive beginning for the early-stage clinical evaluation. The program represents a significant advancement in the development of precision immunotherapies for one of Japan’s most common allergic conditions, affecting approximately 48 million people.
UNITE® and saRNA Technology Aim to Transform Allergy Treatment
Unlike conventional allergy medications that primarily manage symptoms, ITI-9001 is designed to reprogram the immune system by targeting the root cause of Japanese cedar pollen allergy. The investigational vaccine utilizes self-amplifying RNA (saRNA) technology in combination with Immunomic Therapeutics’ proprietary UNITE® platform, which incorporates lysosome-associated membrane protein (LAMP) technology to improve antigen presentation and stimulate strong T-cell immune responses. The vaccine specifically targets CryJ2, one of the major allergens responsible for triggering Japanese cedar pollen allergy.
By enhancing immune recognition of the allergen, ITI-9001 aims to induce long-lasting immune tolerance and potentially deliver durable therapeutic benefits beyond seasonal symptom control. This innovative mechanism positions the therapy among a new generation of RNA-based immunotherapies, reflecting the broader expansion of advanced vaccine technologies beyond infectious diseases into chronic immune-mediated disorders. If successful, the platform could establish a new paradigm for treating allergies through targeted immune modulation instead of repetitive symptomatic treatment.
Phase 1 Trial Evaluates Safety, Dose Selection and Immunogenicity
Advertisement
The Phase 1 clinical trial is being conducted as a single-center, randomized, placebo-controlled study involving adults between 18 and 65 years of age diagnosed with Japanese cedar pollen allergy. The initial phase of the study focuses on evaluating the safety and tolerability of both low-dose and high-dose cohorts, enabling investigators to identify the most appropriate dose for further development. Following dose selection, researchers will compare the selected treatment dose with placebo while assessing both safety and immunogenicity, providing early insights into the vaccine’s ability to stimulate beneficial immune responses.
The rapid initiation of patient enrollment shortly after PMDA clearance demonstrates efficient clinical execution and reinforces the company’s commitment to accelerating innovative allergy therapies. Positive outcomes from this study could support advancement into larger clinical trials designed to evaluate efficacy and long-term disease-modifying potential in patients affected by Japanese cedar pollen allergy.
Clinical Milestone Strengthens HLB’s Innovative Immunotherapy Pipeline
The successful dosing of the first participant represents an important milestone for Immunomic Therapeutics and its parent company HLB, further expanding their portfolio of innovative RNA-based immunotherapies. According to the company, ITI-9001 has been specifically engineered to provide durable immune modulation, addressing the underlying biological mechanisms responsible for allergic disease while potentially overcoming the limitations of current antihistamines, corticosteroids, and conventional allergen immunotherapy. Company leadership emphasized that the ongoing study will establish the vaccine’s initial safety profile while generating valuable immunogenicity data to guide future development.
As global interest continues to grow in precision immunotherapy, self-amplifying RNA technology, and next-generation therapeutic vaccines, the advancement of ITI-9001 highlights the expanding application of advanced vaccine platforms beyond infectious diseases into chronic allergic disorders. If clinical development continues successfully, ITI-9001 could emerge as a promising disease-modifying treatment option capable of improving long-term outcomes for millions of patients suffering from Japanese cedar pollen allergy.
Source: Immunomic Therapeutics press release
